A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
Completed · Phase 1
Conditions studied: T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
In brief
The purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL).
Key facts
- Study ID
- NCT04984356
- Run by
- Allotera Therapeutics
- People needed
- 28
- Starts
- 2022-01-14
- Expected to finish
- 2024-08-08
- Last updated by the study team
- 2025-09-30
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States
- Children's Hospital Los Angeles — Los Angeles, California, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- Washington University — St Louis, Missouri, United States
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
- Vanderbilt University — Nashville, Tennessee, United States
- University of Wisconsin — Madison, Wisconsin, United States
- Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia
- Hospital Saint- Louis — Paris, France
- University Hospital Robert Debre — Paris, France
- Erasmus MC — Rotterdam, Netherlands
- Prinses Maxima Centrum — Utrecht, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.